Resources | NITAG RESOURCE CENTER

2024 ∙ Yemane Berhane, Telahun Teka, Meseret Zelalem, Yohannes Lakew, Amha Mekasha, Bogale Worku, Genet G/Medhin, Liya Wassie, Liya Wondwossen, Mulat Nigus, Samuel Teshome, Shiferaw Mitiku, Solomon Tessema Memirie, Teferi Fenta, Workeabeba Abebe, Yirgu Gebrehiwot

The Ethiopian National Immunization Technical Advisory Group (E-NITAG): Establishment, Achievements and the Future

2024 ∙ NIAC

NIAC updated recommendations for COVID-19 primary schedule vaccination

2024 ∙ ACIP

Use of the Pfizer Pentavalent Meningococcal Vaccine Among Persons Aged ≥10 Years: Recommendations of the Advisory Committee on Immunization Practices ― United States, 2023

2024 ∙ ACIP

Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2024–25 Influenza Season

2024 ∙ ACIP

Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated Recommendations of the ACIP — United States, 2024

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Protein Subunit RSV vaccines (GSK Arexvy or Pfizer Abrysvo) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

ACIP Evidence to Recommendations for Use of Moderna RSV Vaccine (mResvia) in All Adults Aged ≥75 years and in Adults Aged 60–74 at Increased Risk of Severe RSV Disease

2024 ∙ ACIP

GRADE of Protein subunit RSV vaccines (GSK Arexvy and Pfizer Abrysvo) in older adults

2024 ∙ ACIP

GRADE of Moderna mRNA RSV Vaccine (mResvia) in older adults

2024 ∙ NACI

NACI Interpretation Guide – Health Economics